Literature DB >> 17542774

A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin.

Gerard R Barber1, Joseph Lauretta, Ruben Saez.   

Abstract

Gram-positive pathogens are increasingly implicated in today's changing epidemiology of hospital-acquired infections. Staphylococci, streptococci, and enterococci are among the most frequently identified causes of surgical site, complicated skin-structure, and bloodstream infections. In accordance, the use of antimicrobial agents with gram-positive activity, especially those with activity against resistant organisms, has also increased. We describe a septic, neutropenic patient with bacteremia due to Enterococcus gallinarum. Therapeutic options were restricted due to resistance factors of the organism, limited guidance in the medical literature, and the patient's history and underlying condition. Despite these challenges, the patient was successfully treated with a combination of daptomycin and gentamicin and replacement of her indwelling central line. As antimicrobial stewards and diagnosticians, we must bear in mind that selective pressures exerted by the increasing use of agents with gram-positive activity may result in an increased prevalence of organisms such as E. gallinarum.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17542774     DOI: 10.1592/phco.27.6.927

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

1.  Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.

Authors:  Megan K Luther; Marios Arvanitis; Eleftherios Mylonakis; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 2.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 3.  A potential role for daptomycin in enterococcal infections: what is the evidence?

Authors:  Rafael Cantón; Patricia Ruiz-Garbajosa; Ricardo L Chaves; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2010-04-02       Impact factor: 5.790

4.  A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia.

Authors:  Joseph S Bubalo; Ravina Kullar; Richard T Maziarz
Journal:  Ther Adv Infect Dis       Date:  2013-12

Review 5.  The prevention and management of infections due to multidrug resistant organisms in haematology patients.

Authors:  Jason A Trubiano; Leon J Worth; Karin A Thursky; Monica A Slavin
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

6.  Daptomycin use in neutropenic patients with documented gram-positive infections.

Authors:  Kenneth V I Rolston; Dina Besece; Kenneth C Lamp; Min Yoon; Scott A McConnell; Pamela White
Journal:  Support Care Cancer       Date:  2013-08-24       Impact factor: 3.603

Review 7.  Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation.

Authors:  Sehnaz Alp; Murat Akova
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-01-01       Impact factor: 2.576

8.  Daptomycin for Gram-positive Infections in Patients with Neutropenia: Clinical Experience from a European Outcomes Registry.

Authors:  Felix Keil; George L Daikos; Athanasios Skoutelis; Jose Ignacio Barranco Dominguez; Rashidkhan Pathan; Kamal Hamed
Journal:  Adv Ther       Date:  2015-08-04       Impact factor: 3.845

9.  Evaluation of Commercial Myxomatosis Vaccines against Recombinant Myxoma Virus (ha-MYXV) in Iberian Hare and Wild Rabbit.

Authors:  Fábio A Abade Dos Santos; Carina L Carvalho; Pâmela C L G Valente; Henrique Armés; Sylvia S Reemers; Maria C Peleteiro; Inés Calonge Sanz; Kevin P Dalton; Francisco Parra; Margarida D Duarte
Journal:  Vaccines (Basel)       Date:  2022-02-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.